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K2P2.1 (TREK‑1) potassium 
channel activation protects 
against hyperoxia‑induced lung 
injury
Tatiana Zyrianova1, Benjamin Lopez1, Riccardo Olcese2,3, John Belperio4, 
Christopher M. Waters5, Leanne Wong1, Victoria Nguyen1, Sriharsha Talapaneni1 & 
Andreas Schwingshackl1*
No targeted therapies exist to counteract Hyperoxia (HO)‑induced Acute Lung Injury (HALI). We 
previously found that HO downregulates alveolar  K2P2.1 (TREK‑1)  K+ channels, which results in 
worsening lung injury. This decrease in TREK‑1 levels leaves a subset of channels amendable to 
pharmacological intervention. Therefore, we hypothesized that TREK‑1 activation protects against 
HALI. We treated HO‑exposed mice and primary alveolar epithelial cells (AECs) with the novel TREK‑1 
activators ML335 and BL1249, and quantified physiological, histological, and biochemical lung injury 
markers. We determined the effects of these drugs on epithelial TREK‑1 currents, plasma membrane 
potential (Em), and intracellular  Ca2+ (iCa) concentrations using fluorometric assays, and blocked 
voltage‑gated  Ca2+ channels  (CaV) as a downstream mechanism of cytokine secretion. Once‑daily, 
intra‑tracheal injections of HO‑exposed mice with ML335 or BL1249 improved lung compliance, 
histological lung injury scores, broncho‑alveolar lavage protein levels and cell counts, and IL‑6 and 
IP‑10 concentrations. TREK‑1 activation also decreased IL‑6, IP‑10, and CCL‑2 secretion from primary 
AECs. Mechanistically, ML335 and BL1249 induced TREK‑1 currents in AECs, counteracted HO‑induced 
cell depolarization, and lowered  iCa2+ concentrations. In addition, CCL‑2 secretion was decreased 
after L‑type  CaV inhibition. Therefore, Em stabilization with TREK‑1 activators may represent a novel 
approach to counteract HALI.
Oxygen supplementation (hyperoxia; HO) is the most frequently administered therapy in hospitalized patients 
and the mainstay of treatment for hypoxic respiratory failure, regardless of its  etiology1. Clinically, supra-physio-
logic levels of oxygen tension are often tolerated and perceived as a safety net against  hypoxemia2. As a result, in 
the US each year approximately 800,000 patients are exposed to HO therapy at a cost of $1.8 billion to the health 
care  budget3. Importantly, the degree and duration of HO exposure positively correlate with patient morbidity 
and mortality  rates4–6.
Although oxygen therapy can be a life-saving intervention, ample experimental and clinical evidence dem-
onstrates that excessive levels of oxygen supplementation can also initiate and accelerate existing lung injury 
(HO-induced acute lung injury; HALI). Animal models of HALI have been particularly helpful in investigating 
the underlying  mechanisms7, and studies in healthy adults showed that HO exposure causes tracheobronchitis 
and changes in vital capacity, diffusing capacity, and lung permeability within only six hours, and with a sever-
ity that is proportional to the degree of HO  exposure8–13. Experimentally, a similar dose- and time-dependent 
inflammatory response to HO can be reproduced in animal models of  HALI14–16, demonstrating close simi-
larities in lung injury phenotypes between animals and  humans15,17–20. From these studies we learned that the 
molecular mechanisms underlying HALI are complex and include extensive alterations in inflammatory cytokine 
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 secretion14,21,22. Both alveolar epithelial and endothelial cells are injured by HO, but the epithelial layer is the first 
line of defense against inhaled  HO23–25.
Currently, minimizing the duration and amount of HO exposure of patients (“permissive hypoxemia”) repre-
sents the only clinical approach to limit HALI, and so far no molecular targets have been identified that translate 
into improved patient  outcomes26. However, minimizing HO exposure is complicated by the lack of consensus 
in defining the lower limits of permissive hypoxemia, which would allow us to clinically differentiate beneficial 
from injurious levels of HO  therapy27,28.
In our search for new molecular targets against HALI, we recently identified epithelial  K2P2.1 (TREK-1)  K+ 
channels as important regulators in the development and progression of  HALI29–32. TREK-1 channels belong 
to the family of 2-pore domain (K2P)  K+ channels, which are generally known for their unusual gating proper-
ties leading to so-called “leak  K+ currents” that stabilize the resting plasma membrane potential (Em)33,34. In 
general, K2P channels, including TREK-1, are widely expressed in body  tissues35–41, but their role in the lung 
remains largely unknown. Using in vivo and in vitro models of HALI, we previously discovered that HO exposure 
decreases the expression of TREK-1 channels in mouse lungs and alveolar epithelial cells, and accelerates alveolar 
inflammation and barrier  dysfunction30,42,43. These findings sparked the hypothesis that despite HO-mediated 
TREK-1 downregulation, pharmacological activation of the remaining subset of TREK-1 channels can protect 
against HALI. To test this hypothesis, in this study we explored the potential protective effects and underlying 
mechanisms of two novel TREK-1 activating compounds (ML335, BL1249) using in vivo and in vitro models 
of HALI.
Results
Intra‑tracheal administration of TREK‑1 activating compounds protects mice against 
HO‑induced acute lung injury (HALI). Building on our previous findings that HO downregulates 
TREK-1  expression42, we determined whether pharmacological activation of the remainder subset of TREK-1 
channels can counteract the injurious effects of HO on mouse lungs. We treated WT mice with once-daily 
intra-tracheal (i.t.) injections of the TREK-1-activating compounds ML335 or  BL124944,45, or an equimolar drug 
vehicle control, for a total of 3 injections over the 72-h HO or room air (RA) exposure period. Histological 
analysis (Fig. 1A) and blinded Lung Injury Scoring (LIS; Fig. 1B) of H&E-stained mouse lung sections revealed 
that under RA conditions administration of ML335 and BL1249 had no damaging effect on lung histology. As 
expected, exposure of mice to HO caused significant inflammatory changes (panel d), as also evidenced by an 
increase in LIS. Importantly, once-daily i.t. injections of ML335 or BL1249 during HO exposure substantially 
reduced these HO-induced injurious effects (Fig. 1A panels e and f, and B). Similarly, analysis of physiological 
parameters of lung injury also revealed protective effects of TREK-1 activation in HO-exposed mice, as evi-
denced by improvements in quasi-static lung compliance (Fig. 1C), and a reduction in BAL fluid protein levels 
and total cell counts (Fig. 1D, E). These data suggest that pharmacological activation of TREK-1 channels can 
counteract HALI in an experimental mouse model.
TREK‑1 activation decreases inflammatory cytokine concentrations in the BAL fluid of HO 
exposed mice. To investigate whether the TREK-1-mediated improvements in histological and physiolog-
ical lung injury parameters are associated with a reduction in inflammatory cytokine concentrations in HO 
exposed mice, we measured IL-6, IP-10, CCL-2, TNF-α, MIP-1α and IL-10 concentrations in BAL fluid (Fig. 2). 
We found that under room air conditions once-daily i.t. injections of ML335 or BL1249 had no effect on baseline 
cytokine secretion. Exposure of mice to 72 h HO resulted in an increase in IL-6, IP-10, CCL-2, TNF-α and IL-10 
concentrations in the BAL fluid. Importantly, once-daily i.t. injections with ML335 or BL1249 during the 72 h 
of HO exposure decreased HO-induced IL-6 and IP-10 levels in the BAL fluid, but not CCL-2, TNF-α or IL-10. 
MIP-1α concentrations were neither affected by HO exposure nor treatment of mice with the TREK-1 activating 
compounds.
TREK‑1 activity regulates inflammatory cytokine secretion from primary mouse AT2 cells. To 
evaluate whether the protective effects of TREK-1 activation observed in vivo were due to TREK-1-mediated 
attenuation of inflammatory cytokine secretion from alveolar epithelial cells, we exposed freshly-isolated mouse 
AT2 cells to HO or RA in the presence or absence of ML335 or BL1249, and quantified inflammatory cytokine 
secretion in culture supernatants (Fig. 3). We chose the shorter (24-h) HO exposure period (compared to 72 h 
in vivo) for freshly isolated AT2 cells, since in this cell type 72 h of HO exposure resulted in > 60% AT2 cell death 
(data not shown). Importantly, real-time PCR experiments and immunofluorescence (IF) microscopy imaging 
confirmed HO-induced TREK-1 downregulation after 24 h in this cell-type (Supplementary Fig. 1A,B). Simi-
lar to our findings in the BAL fluid, HO exposure increased secretion of IL-6 and CCL-2 from freshly isolated 
mouse AT2 cells, and this effect was counteracted by concomitant treatment of cells with the TREK-1 activators 
ML335 or BL1249. Furthermore, HO exposure did not induce MIP-1α secretion from AT2 cells, similar to our 
findings in the BAL fluid. In contrast to our findings in the BAL fluid, HO exposure did not induce IP-10, TNF-α 
or IL-10 secretion from primary AT2 cells, and treatment with ML335 or BL1249 had no effect on the secretion 
of these cytokines at baseline or after HO exposure (Fig. 3).
TREK‑1 activity regulates inflammatory cytokine secretion from primary human alveolar epi‑
thelial cells (HAECs). To determine whether the TREK-1-mediated protective effects observed in mice and 
mouse AT2 cells can be reproduced in primary human alveolar epithelial cells (HAEC), we exposed HAEC to 
72 h HO in the presence or absence of the TREK-1 activators ML335 or BL1249 (Fig. 4). Initial dose–response 
experiments revealed that BL1249 and ML335 are not cytotoxic at the doses used in this study (Supplementary 
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Fig. 2). In contrast to primary mouse AT2 cells, viability of HAECs after 72 h HO exposure remained > 70% (data 
not shown), and this exposure period closely mimicked our in vivo model. Similar to our findings in primary 
mouse AT2 cells, HO exposure increased secretion of IL-6 and CCL-2 from HAECs, but did not induce TNF-α 
or MIP-1α secretion. Of note, overall concentrations of TNF-α and MIP-1α were quite low in these cells. In 
contrast to primary mouse AT2 cells but similar to BAL fluid, HO also increased secretion of IP-10 and IL-10 
from HAECs. Importantly, treatment of HAECs with the TREK-1 activators ML335 or BL1249 inhibited the 
HO-induced secretion of IL-6, IP-10, CCL-2, and IL-10.
Altogether, these findings suggest that TREK-1 activation regulates HO-induced inflammatory cytokine 
secretion both in vivo and in vitro, but differences can be observed between overall cytokine concentrations in 
BAL fluid and cultured primary epithelial cells.
ML335 and BL1249 activate TREK‑1 currents in primary AT2 cells. Although the specificity of 
ML335 and BL1249 for TREK-1 channels has previously been validated in heterologous expression  systems44,46,47, 
the effectiveness of these compounds has never been demonstrated in lung cells. To confirm that both com-
pounds activate TREK-1 currents in a physiologically relevant system and cell type, we used fluorescence-based, 
 K+-sensitive FLIPR assays to demonstrate the effects of ML335 and BL1249 on  K+ currents in primary mouse 
Figure 1.  TREK-1 activation with the novel compounds ML335 and BL1249 protects form HO-induced 
lung injury: (A) Representative images of H&E-stained lung sections of WT mice exposed to either room air 
(panels a-c) or HO (panels d-f) for 72 h. All mice received once-daily, intra-tracheal (i.t.) injections of ML335, 
BL1249, or a vehicle control (no drugs) via brief endotracheal intubation. HO exposure caused significant lung 
injury (panel d), which was ameliorated by concomitant treatment with ML335 or BL1249 (panels e, f). (B) 
Summary of cumulative Lung Injury Scores of n = 5 independent experiments. (C–E) The HO-induced decrease 
in semi-static lung compliance, and increase in BAL fluid total protein and cell count were counteracted by 
ML335 and BL1249. Data are represented as Box-Whisker plots with medians, 1st and 3rd quartiles, and max 
and min values; n = 5–9; ^compared to mice injected with a vehicle control and exposed to room air (no drugs), 
*compared to HO exposed mice; p ≤ 0.05.
4
Vol:.(1234567890)
Scientific Reports |        (2020) 10:22011  | https://doi.org/10.1038/s41598-020-78886-y
www.nature.com/scientificreports/
AT2 cells (Fig. 5). FLIPR assays exploit the permeability of thallium  (Tl+) for open  K+  channels48. After loading 
AT2 cells with the fluorescent dye, the addition of extracellular  Tl+ creates a concentration gradient for  Tl+ to 
enter the cells. The resultant increase in relative fluorescence is proportional to the open probability of plasma 
membrane  K+ channels, and thus represents a measure of the functional activity of  K+ channels. Therefore, 
under unstimulated conditions (no drugs), the  Tl+-induced fluorescence represents the sum of background  K+ 
currents, while after ML335 or BL1249 treatment an increase in fluorescence represents activation of TREK-
1-specific  K+ currents (Fig. 5). Our data show that under RA conditions both compounds, ML335 and BL1249, 
activate TREK-1-specific  K+ currents (Fig. 5A). Importantly, these effects were maintained after 24 h of HO 
exposure (Fig. 5B).
Activation of TREK‑1 channels hyperpolarizes the plasma membrane potential (Em) of pri‑
mary AT2 cells. To determine whether the protective effects of ML335 and BL1249 are mediated by TREK-
1-induced alterations in the Em, we performed Em-sensitive FLIPR assays on primary mouse AT2 cells under 
RA and HO conditions (Fig.  6). Once cells are loaded with the Em-sensitive fluorescent dye, a decrease in 
relative fluorescence represents Em hyperpolarization, whereas an increase in fluorescence represents Em depo-
larization. Since both TREK-1 activating compounds, ML335 and BL1249, had identical effects (i) in our in vivo 
Figure 2.  Effects of ML335 and BL1249 on BAL fluid cytokine concentrations (A–F): HO exposure increased 
IL-6, IP-10, CCL-2, TNF-α, and IL-10 concentrations, but not MIP-1α. Once-daily i.t. treatment with ML335 or 
BL1249 decreased HO-induced IL-6 and IP-10 levels, but not CCL-2, TNF-α or IL-10. Data are represented as 
Box-Whisker plots with medians, 1st and 3rd quartiles, and max and min values; n = 5–9; ^compared to mice 
exposed to room air and treated with a vehicle control (no drugs), *compared to HO exposed mice; p ≤ 0.05.
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model, (ii) on inflammatory cytokine secretion, and (iii) on TREK-1 current activation, we used only BL1249 
for this part of the study. We found that under room air conditions, activation of TREK-1 channels with BL1249 
results in Em hyperpolarization (= a decrease in fluorescence; Fig.  6A) of primary AT2 cells. Similar to the 
observed activation of TREK-1 currents with BL1249 (Fig. 5), the BL1249-induced Em hyperpolarization also 
persisted after HO exposure (Fig. 6B). Importantly, these studies also revealed that HO itself causes Em depolari-
zation when compared to cells kept at RA, as evidenced by a higher baseline fluorescence value in HO-exposed 
cells (see RED arrows on the Y-axis → in Fig. 6A, B and summarized in C).
TREK‑1 activation decreases intracellular  Ca2+ (iCa) levels during HO exposure. Since inflam-
matory cytokine secretion is commonly associated with an increase in iCa concentrations, we used Fluo-4 assays 
to determine the effects of TREK-1 activation on iCa levels in primary mouse AT2 cells (Fig. 7). Importantly, 
following 24 h of HO exposure, AT2 cells contained higher iCa concentrations than cells kept at RA (PURPLE 
arrows on the Y-axis → in Fig. 7A,B and summarized in C). In cells kept at RA, activation of TREK-1 channels 
Figure 3.  TREK-1 activation with ML335 and BL1249 regulates cytokine secretion from primary mouse AT2 
cells: HO exposure increased IL-6 and CCL-2 secretion, which were inhibited by concomitant treatment with 
ML335 or BL1249 (A, C). In contrast, IP-10, TNF-α, MIP-1α and IL-10 levels were not affected by TREK-1 
activation in room air- or HO-exposed AT2 cells (B,D,E,F). Data are represented as Box-Whisker plots with 
medians, 1st and 3rd quartiles, and max and min values; n = 5–9; ^compared to cells treated with a vehicle 
control and exposed to room air (no drugs), *compared to HO exposed cells; p ≤ 0.05.
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:22011  | https://doi.org/10.1038/s41598-020-78886-y
www.nature.com/scientificreports/
and Em hyperpolarization with BL1249 had no effect on iCa levels, likely due to the already low iCa levels in 
resting cells (Fig. 7A). In HO-exposed cells, on the other hand, TREK-1 activation with BL1249 decreased the 
HO-induced elevation in iCa levels (Fig. 7B).
Altogether, these findings highlight the TREK-1 activating effects and resultant Em hyperpolarization caused 
by ML335 and BL1249 in primary alveolar epithelial cells, and demonstrate that these effects persist under HO 
conditions, making TREK-1 activation a feasible approach to modulate the Em and iCa concentrations during 
HO exposure.
Regulation of inflammatory cytokine secretion by voltage‑gated  Ca2+  (CaV) channels. Em 
depolarization, as observed with HO exposure and counteracted by TREK-1 activation, results in opening of 
 CaV channels in many cell types, and the resultant increase in iCa concentrations is commonly a trigger for 
downstream inflammatory cytokine  secretion49,50. Therefore, we measured HO-induced cytokine secretion 
Figure 4.  TREK-1 activation with ML335 and BL1249 regulates cytokine secretion from primary human 
alveolar epithelial cells (HAEC): HO exposure increased secretion of IL-6, IP-10, CCL-2 and IL-10, and this 
effect was counteracted by ML335 or BL1249 (A,B,C,F). In contrast, TNF-α and MIP-1α levels were not affected 
by TREK-1 activation in room air- or HO-exposed HAECs (D,E). Data are represented as Box-Whisker plots 
with medians, 1st and 3rd quartiles, and max and min values; n = 4–8; ^compared to cells treated with a vehicle 
control and exposed to room air (no drugs), *compared to HO exposed cells; p ≤ 0.05.
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from primary mouse AT2 cells after blocking N- and P/Q-type  CaV channels with ω-conotoxin  MVIIC51, and 
L-type  CaV channels with  nifedipine52 (Fig. 8). Since in primary AT2 cells HO exposure predominantly induced 
secretion of IL-6 and CCL-2 (Fig.  3), we focused on the role of  CaV channels in the secretion of these two 
cytokines. Interestingly, while HO-induced IL-6 secretion was not dependent on  CaV channel activity, CCL-2 
secretion was inhibited by the L-type  CaV channel blocker nifedipine, but not by the N- and P/Q-type  CaV chan-
nel blocker ω-conotoxin MVIIC. Secretion of IP-10, TNF-α, MIP-1α and IL-10 from AT2 cells was not affected 
by ω-conotoxin MVIIC or nifedipine (data not shown).
Altogether, these findings suggest that regulation of inflammatory cytokine secretion via TREK-1-induced 
Em hyperpolarization and inhibition of  CaV channel activation could explain some, but not all, of the TREK-1 
protective effects seen in our in vivo model.
Discussion
In this study we propose activation of TREK-1 K+ channels as a potentially new therapeutic approach against 
HALI, since currently no targeted interventions exist that translate into improved patient outcomes. Recent 
in vitro studies suggest that overexpression of certain microRNAs (miR16, miR21-5) may protect cultured AT2 
cells against HO-induced  apoptosis53–55, and multiple biomarker studies have aimed at predicting the risk of 
HALI in  patients56,57. In addition, neutralizing therapies against individual cytokines, including IL-6, TNF-α 
and CCL-2, have yielded variable results at best in improving inflammatory  responses58–61.
Given these challenges, we are particularly interested in identifying strategies that can regulate multiple 
inflammatory pathways simultaneously, such as the manipulation of the plasma membrane potential (Em). 
We previously discovered that HO downregulates TREK-1 K+ channel expression in lung tissue and alveolar 
epithelial cells, which correlates with worsening lung injury and alterations in multiple inflammatory cytokines 
(IL-6, CCL-2, RANTES, and IL-1β)29–32,42. Importantly, this HO-induced decrease in TREK-1 expression leaves 
a remainder subset of TREK-1 channels suitable for pharmacological activation. Although channels of the K2P 
family are known for their so-called “leak  K+ currents” (a constant, slow  K+ efflux that stabilizes the Em), TREK-1 
channels are actually thought to be closed at  baseline34,62. This idea is supported by our own data in alveolar 
epithelial cells (Fig. 5) showing that TREK-1 currents can readily be induced by our channel activators ML335 
and  BL124944,46,47, thus making TREK-1 channels a feasible target for therapeutic activation.
So far, most of the biophysical characterization of TREK-1 channels has occurred under non-physiological 
conditions in heterologous expression  systems44,63,64, and little is known about their functions in physiologically-
relevant models. Our study is the first to (a) report the safety and efficacy of the novel TREK-1 activating com-
pounds ML335 and BL1249 in an in vivo system, and (b) highlight the protective effects of TREK-1 activation in 
a lung injury model by measuring clinically relevant parameters. The only other reports suggesting a potentially 
protective role for TREK-1 activation used models of hypoxic-ischemic brain injury and atrial fibrillation/heart 
 failure65–67. Interestingly, effects of single nucleotide polymorphisms (SNPs) in the human TREK-1 gene have 
been reported in the same two organs, and predict resistance to antidepressant  medication68, and an increased 
risk for atrial  tachycardias69. However, until now a similar protective effect for TREK-1 channels has not been 
reported in any other organ.
The importance of inflammatory mediators in the development and progression of HALI is well-estab-
lished14,70, including the cytokines reported in this study: IL-6, IP-10, CCL-2, TNF-α, MIP-1α, and IL-1017,21. 
Figure 5.  ML335 and BL1249 activate TREK-1 currents in primary mouse AT2 cells: Summary of n = 4–5 
independent FLIPR curves (means ± SEM) showing that the TREK-1 activating compounds ML335 or BL1249 
induce TREK-1 specific  K+ currents under both room air and HO conditions (A,B). In both room air and 
HO-treated cells, baseline background  K+ currents were observed (No drug). *compared to vehicle control 
(No drug) at room air, ^compared to vehicle control (No drug) after HO exposure; p ≤ 0.05, n = 4–5, individual 
experiments were run in triplicates.
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In general, IL-6, IP-10, TNF-α and MIP-1α are known for their proinflammatory properties, while CCL-2 can 
exert pro-71,72 or anti-inflammatory73,74 effects, and IL-10 is considered a predominantly anti-inflammatory 
 cytokine75,76. More recently it has become increasingly clear that the inflammatory phenotypes observed in 
various lung injury models are determined by complex interactions between multiple cytokines. For example, 
despite the well-documented proinflammatory effects of IL-6 and its association with poor outcomes in ARDS 
 patients77, IL-6 also induces anti-inflammatory IL-10 secretion as a counter-regulatory  response78, and a recent 
study suggests that IL-6 protects mice from LPS- and mechanical ventilation-induced lung  injury79. In our HALI 
model we found increased levels of both IL-6 and IL-10 in the BAL fluid of HO-exposed mice. Interestingly, 
while TREK-1 activation decreased HO-induced BAL fluid IL-6 levels, IL-10 levels remained elevated even after 
TREK-1 activation, potentially acting synergistically with the protective effects of TREK-1 activation. It is impor-
tant to note that both lung resident and immune cells contribute to the cytokine levels measured in BAL fluid, 
and it is quite likely that in our in vivo model the TREK-1 activators affect cytokine secretion from multiple cell 
types. In this study we focused on epithelial cells since previously we did not find alterations in TNF-α release 
from TREK-1-deficient alveolar macrophages, and the single cell RNA-seq database LungGENS only reports 
low levels of TREK-1 postnatally in endothelial  cells42,80.
Our results report for the first time (1) the expression of functional TREK-1 channels on primary mouse AT2 
cells and human alveolar epithelial cells (HAEC), and (2) the effects of Em manipulation via TREK-1 channels 
on inflammatory cytokine secretion and iCa concentrations in a clinically relevant model of HALI. Since in 
clinical practice the timing of HO therapy is entirely under the control of the healthcare provider, administra-
tion of TREK-1 activators simultaneously with initiation of HO therapy is a clinically feasible approach. Of note, 
although in animal models the injurious effects of HO on previously healthy lungs have been extensively studied, 
Figure 6.  TREK-1 activation causes plasma membrane potential (Em) hyperpolarization: Representative 
curves of Em-sensitive FLIPR assays showing that TREK-1 activation with BL1249 causes Em hyperpolarization 
in primary mouse AT2 cells under both room air and HO conditions (A,B), as indicated by a decrease in 
fluorescence values. Red arrows on the Y-axis indicate relative fluorescence values reflective of the baseline Em 
value in room air and HO exposed AT2 cells, demonstrating that HO exposure itself causes Em depolarization 
(higher baseline fluorescence value in B than A; *BL1249 compared to no drug/vehicle control, p ≤ 0.05). (C) 
Summary of baseline Em values of RA- vs. HO-exposed AT2 cells averaging n = 6 independent experiments for 
each condition. Data are represented as Box-Whisker plots with medians, 1st and 3rd quartiles, and max and 
min values; ^compared to room air exposed AT2 cells; p ≤ 0.05, individual experiments were run in triplicates.
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in humans the exact degree and duration of HO exposure that results in symptomatic and clinically-relevant 
injury remains a matter of intense  discussion81.
From studies in macrophages, neutrophils and mast cells, we learned that changes in the Em commonly 
precede secretory  events82,83, but the molecular mechanisms regulating inflammatory cytokine secretion from 
lung resident cells remain incompletely understood. Furthermore, studies in lung endothelial cells, revealed 
that the resting Em can vary among cell phenotypes. Reported Em values in endothelial cells range from − 30 
to − 60 mV84,85, and exposure of pulmonary artery endothelial cells to low oxygen concentrations (hypoxia) has 
been reported to cause Em  depolarization86. Similar variations in Em depending on the cellular phenotype have 
also been documented in lung epithelial cells, including rat AT2 cells (− 30 mV)87,88, rabbit AT2 cells (− 60 mV)89, 
human bronchial epithelial cells (− 20 to − 45 mV)90,91, and nasal epithelial cells (− 15 to − 30 mV)91,92. Limited 
information form human ex vivo studies point towards Em values between − 15 and − 20 mV in bronchial epi-
thelial  cells91,93. Notably, other studies estimate the resting Em in AT2 cells as low as 0 to − 5 mV94,95. Despite 
these ranges in Em for lung resident cells, it is important to realize that the Em of epithelial and endothelial 
cells is much lower than the Em of excitable cells such as neurons and cardiomyocytes, in which the Em ranges 
between − 60 and − 90 mV96,97. Since these latter cell types are more hyperpolarized at baseline (i.e. more negative 
Em values), they require a much stronger depolarization stimulus for a biological response to occur, such as the 
opening of voltage-gated  Ca2+  (CaV) channels and subsequent  Ca2+ influx. In contrast, in the more depolarized 
epithelial and endothelial cells, a much smaller Em perturbation can reach the threshold for  CaV channel acti-
vation, and trigger downstream responses. Conversely,  K+ efflux, as caused by TREK-1 activation with BL1249 
Figure 7.  TREK-1 activation decreases intracellular  Ca2+ (iCa) concentrations in HO-exposed primary mouse 
AT2 cells: (A,B) Representative curves of  Ca2+-sensitive Fluo-4 assays showing that HO-exposed AT2 cells 
contain higher iCa concentrations than RA-exposed cells, as indicated by an increase in fluorescence values 
(purple arrows on Y-axes). TREK-1 activation with BL1249 has no effect on iCa concentrations in RA-exposed 
cells, but decreases iCa levels in HO-exposed cells (*BL1249 compared to no drug/vehicle control, p ≤ 0.05). 
A summary of n = 6 independent experiments is shown in C; data are represented as Box-Whisker plots with 
medians, 1st and 3rd quartiles, and max and min values; ^compared to room air exposed AT2 cells; p ≤ 0.05, 
individual experiments were run in triplicates.
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(Fig. 6A), moves the Em away from this critical threshold towards more negative (hyperpolarized) Em values, 
and can counteract depolarization-induced cell activation processes.
HO-mediated depolarization events have been reported in mitochondrial membranes of pulmonary endothe-
lial  cells98, but our study is the first to show HO-induced Em depolarization in primary epithelial cells. Interest-
ingly, in carotid body cells hypoxia, not hyperoxia, causes Em depolarization and increases  iCa2+ concentrations, 
while HO inhibits both of these  processes99,100. In contrast to these studies, we demonstrate that primary epithelial 
cells respond to HO exposure by increasing  iCa2+ levels (Fig. 7), and we propose that this response is mediated 
by HO-induced Em depolarization that can be counteracted by TREK-1 activation (Figs. 6, 7).
Interestingly, although it is well-known that both extracellular  Ca2+ influx and  Ca2+ release from intracel-
lular stores can increase  iCa2+ levels, we found that in primary mouse AT2 cells only secretion of CCL-2, but 
not IL-6, IP-10, TNF-α, or MIP-1α, was dependent on  Ca2+ influx via  CaV channels (Fig. 8). The lack of effect 
of ω-conotoxin MVIIC on cytokine secretion suggests that  Ca2+ influx via N-, and P/Q-type  CaV channels is 
unlikely to contribute to these processes. In addition to the novelty and importance of our data, these findings 
also indicate that  Ca2+ release from intracellular stores is likely to be involved in the observed secretory processes.
Although upregulation of CCL-2 in bronchial and alveolar epithelial cells under inflammatory conditions 
is well-documented101–103, it remains a matter of intense discussion whether CCL-2 secretion in the lung is a 
 Ca2+-dependent process, and may ultimately depend on the specific cell type and inflammatory environment. In 
both immortalized and primary lung epithelial cells, inhibition of  Ca2+ sensing,  Ca2+ influx, and  iCa2+ release all 
prevent CCL-2 secretion, and in some instances also IL-6  release104,105. Conversely, it is known that in immune 
cells CCL-2 itself can increase  iCa2+  concentrations106, demonstrating the complex interactions underlying CCL-2 
secretion. One study showed that the chemotactic function of CCL-2 can occur in the absence of any changes in 
 iCa107, and in an LPS-induced lung injury model inhibition of cellular  Ca2+ sensing receptors (CaSR) decreased 
IL-6 and TNF-α, but not CCL-2, concentrations in the serum and BAL  fluid104.
Since in our model inhibition of  CaV channels decreased CCL-2 secretion but no other measured cytokines, 
we should consider the possibility that TREK-1-induced changes in Em could be directly sensed by a voltage-
sensitive protein at the plasma membrane level. For this to occur, such a protein would need to contain one 
or more transmembrane segments with free charges that can induce a so-called “gating current” following an 
alteration in Em. Although membrane-bound voltage sensors are well-characterized in the brain and  heart108,109, 
in the lung this important topic has yet to be explored.
We previously reported an important role for TREK-1 in HALI using a TREK-1-deficient mouse  model42, 
which revealed a similar injurious phenotype as can be obtained with HO-induced TREK-1  downregulation42. 
Figure 8.  Effects of voltage-gated  Ca2+ channel  (CaV) inhibition on cytokine secretion from primary mouse 
AT2 cells: HO exposure increased IL-6 (A) and CCL-2 (B) secretion compared to RA-treated cells. Inhibition 
of N- and P/Q-type  CaV channels with ω-conotoxin MVIIC or L-type  CaV channels with nifedipine revealed 
that IL-6 secretion occurred independently of  CaV channel activity, whereas CCL-2 secretion was dependent on 
L-type  CaV channels (inhibited by nifedipine) but not N- and P/Q-type channels (lack of ω-conotoxin MVIIC 
effect). Data are represented as Box-Whisker plots with medians, 1st and 3rd quartiles, and max and min values; 
n = 3–6; ^compared to cells treated with a vehicle control and exposed to room air (No drugs), *compared to 
HO exposed cells; p ≤ 0.05.
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In this study, we now shed some light on how TREK-1 may regulate downstream signaling cascades during HO 
exposure. Based on the current and our previous studies, we propose that the primary mechanism underlying 
the HO-mediated effects on TREK-1 signaling consists in a decrease in TREK gene and protein expression 
levels, rather than potential HO-mediated post-translational modifications of the TREK-1 protein structure. Of 
note, in HEK293 cells, posttranslational TREK-1 phosphorylation has been reported, and resulted in TREK-1 
 inhibition110. However, even if such changes occurred in the lung, they do not seem to interfere with the activa-
tion effects of BL1249 and ML335 on TREK-1 channels. Since BL1249 and ML335 are designed to bind and 
functionally activate wildtype TREK-1 channels, substantial HO-induced structural/posttranslational changes 
to the TREK-1 structure are unlikely the cause for our reported outcomes. In fact, one of the key findings of this 
study is that BL1249 and ML335 can activate TREK-1 channels and ameliorate injury despite any HO-induced 
changes in the intra- and extracellular cellular environments. Notably, we previously reported TREK-1 expres-
sion in both AT1 and AT2 cells from mouse lung slices, as well as mouse alveolar macrophages (AMs), but saw 
only weak TREK-1 staining in the mouse lung endothelium. Interestingly, in that study we also found that LPS-
induced TNF-α release from mouse AMs appears to occur independently of TREK-131, suggesting that epithelial 
TREK-1 channels are the primary target for BL1249 and ML335 in our HALI model.
In conclusion, we report for the first time the functional expression of TREK- 1K+ channels on primary 
alveolar epithelial cells. We show that pharmacological activation of TREK-1 channels during HO exposure is 
a novel and clinically feasible approach to protect against HALI by reducing inflammatory cell recruitment and 
barrier dysfunction in the lungs, which may at least in part be mediated by inhibition of inflammatory cytokine 
secretion. However, additional studies are required to identify other potential effector mechanisms contributing 
to TREK-1-mediated protection, which should include ROS production, cell death pathways, and inflamma-
some activation.
Materials and methods
Mice. C57bl/6 wild-type (WT) mice aged 9–12 weeks were obtained from Jackson Laboratories (www.jax.
org). Mice were housed in same-sex groups of up to 5 mice per cage and provided with food and water ad libi-
tum. For experimental purposes, mice were age- and gender-matched as closely as possible.
Mouse hyperoxia (HO) exposure. Using a rodent HO chamber and a 5-L oxygen concentrator (DeVil-
biss Healthcare, #525DS), we exposed mice to HO  (FiO2 = 0.8–0.9 inside the chamber) for 72 h in their native 
cages with free access to food and water. Temperature, humidity and oxygen concentrations were monitored 
continuously using commercially available sensors (AcuRite 00325A1 for temperature and humidity; Hudson-
RCI5800 for oxygen concentrations). During HO exposure, mice lost less than 10% of weight and appeared 
overall healthy. No deaths were observed. Control mice were exposed to room air (RA) for the same time period 
in their native cages.
TREK‑1 activating compounds. We used two novel TREK-1 activating compounds, ML335 and BL1249. 
ML335 has been synthesized and validated by our collaborator Dr. Minor at  UCSF44, who provided this com-
pound to us as gift. BL1249 has most recently become commercially available (Tocris)45. Stock solutions for 
ML335 (100 mM) and BL1249 (100 mM) were prepared in DMSO. For in vivo experiments, we used a final 
concentration of 100 μM ML335 and 200 μM BL1249 in sterile PBS. For in vitro experiments in primary cells, 
we used a final concentration of 100 μM (60 μg/kg) ML335 and 10 μM (100 μg/kg) BL1249 suspended in culture 
media. Vehicle controls for all experiments contained equimolar amounts of the DMSO.
Intra‑tracheal injections. During the 72 h of RA or HO exposure, mice were injected once-daily intratra-
cheally (i.t.) via brief endotracheal intubation with either 40μL of the TREK-1 activating compounds ML335, 
BL1249, or a vehicle control in sterile PBS. Briefly, for i.t. injections, mice underwent brief inhaled isofluorane 
(2–5%) anesthesia until they lost consciousness, and were then suspended by their incisors on a 3.0 silk suture 
mounted on a 45 degree-angled stand. The tongue was gently extracted from the mouth and moved to the side 
using blunt forceps in order to visualize the vocal cords. Using fiberoptic guidance, a 20-gauge angiocatheter was 
passed through the vocal cords into the subglottic area, and 40 μL of drug or vehicle control were injected with a 
micropipettor. Mice were then placed back into their native cages and allowed to recover under a warming lamp 
until fully awake. No perianesthetic deaths were associated with this procedure.
Quasi‑static lung compliance measurements. Following RA or HO exposure, a tracheostomy was 
performed using an 18-gauge steel catheter under general ketamine/xylazine anesthesia (intraperitoneal, 10 mg/
kg ketamine; 20  mg/kg xylazine). Quasi-static lung compliance was measured using the Flexivent system 
(SQIREC). Pressure–volume curves (P–V) were recorded, and each set of P–V curves was preceded by an infla-
tion maneuver to total lung capacity to insure equal standard lung volumes for each experiment. Quasi-static 
lung compliance was calculated by fitting data derived from the P–V curves to the Salazar-Knowles equation as 
previously  described111. Rectal temperatures were maintained in physiologic range using a heat lamp. All experi-
ments were terminal.
Broncho‑alveolar lavage (BAL) fluid collection and lung histology. Following Flexivent measure-
ments, BAL fluid was collected from all mice using a 1 ml syringe attached to the tracheostomy catheter. Two 
wash-outs were performed with 1 ml PBS/0.6 mM EDTA for BAL protein and cell count determination, and 1 ml 
PBS/0.5% BSA for cytokine assays. All samples were immediately placed on ice. Total BAL protein concentra-
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tions were measured using the Bradford assay (BioRad), and total BAL cell counts were performed using a Diff-
Quick stain (Fisher Scientific). Thereafter, lung tissue was harvested and processed for histological examination. 
Briefly, the lungs were gently retrograde perfused via the right ventricle with 10 ml ice-cold PBS to remove red 
blood cells. Lung tissue was then removed en bloc and immediately perfused and fixed in 4% formalin. Paraffin-
embedded sections were cut into 4 µm thick tissues slices using a Microtome, and H&E-stained for histological 
analysis. Lung Injury Scores (LIS) were determined by an investigator blinded to the experimental conditions 
on H&E-stained lung sections as previously described, using the following 3 criteria: (1) interstitial and alveolar 
edema, (2) cellular infiltrate, and 3) parenchymal and perivascular hemorrhage. Each criterion was assigned a 
score between 0–3, with “0” representing no injury, “1” representing mild injury, “2” representing moderate 
injury, and “3” representing severe injury. Five randomly assigned high power fields per slide were scored under 
40 × magnification on a Motic AE20/21 inverted microscope, and scores were averaged for each criterion. Using 
the sum of these averages, a composite histological LIS was calculated for each experimental group.
Primary mouse and human alveolar epithelial cells. Primary mouse alveolar type-2 cells (AT2) cells 
were freshly isolated as previously  described112. We obtained in average 3–5 × 106 AT2 cells per mouse lung 
with > 90% purity as assessed by immunostaining for pro-SPC. All experiments were performed in accordance 
with the guidelines of the Institutional Animal Care and Use Committee at the University of California Los 
Angeles. Freshly isolated AT2 cells were seeded to 70–80% confluence at a density 3.5 × 106 cells per well in 6-well 
tissue culture plates coated with fibronectin. Cells were maintained in DMEM cell culture medium containing 
10% FBS, 4 mM glutamine, 1% penicillin/streptomycin, and 0.25 µM amphotericin B. All experimental inter-
ventions were started on day 2 after AT2 cell isolation.
Primary Human Alveolar Epithelial Cells (HAEC) were purchased from ScienCell (#3200), cultured accord-
ing to the company’s instructions, and used at a passage numbers < P5. Since these cell suspensions are directly 
isolated from donated human lung tissue, they contain mixed populations of AT1 and AT2 cells.
HO exposure of cells. HO exposure of cells was performed using a cell culture-compatible HO chamber. 
HAEC were exposed to 72 h of HO to mimic our in vivo HO protocol. Since in freshly isolated mouse AT2 cells 
we observed substantial cell death after 72 h of HO exposure  (FiO2 0.8–0.9), we limited HO exposure to 24 h for 
these cells. Controls for each cell type were cultured at room air for the respective time intervals. During the HO 
or RA exposure period, cell suspensions were treated with a one-time dose of the TREK-1 activating compounds 
ML335 (100 μM) or BL1249 (10 μM), or an equimolar DMSO vehicle control. Under all experimental condi-
tions cell viability remained greater than 75% as determined by Trypan Blue staining. To assure that BL1249 and 
ML335 were not cytotoxic at the doses used, we performed dose–response experiments using two cell viability 
assays, CCK-8 (APExBIO) and XTT (Biotium).
TREK‑1 gene and protein expression. We used real-time PCR and IF microscopy to confirm HO-
induced TREK-1 downregulation after 24 h in freshly isolated mouse AT2 cells. Briefly, for PCR experiments 
total RNA was isolated using a Qiagen RNeasy Mini Kit (Hilden, Germany), 1 μg RNA was reverse transcribed 
with a High Capacity cDNA Reverse Transcription kit (Applied Biosystems), and amplified by semi-quantita-
tive real-time PCR (TaqMan) with primers specific for TREK-1 (KCNK2; Applied Biosystems). For IF micros-
copy, mouse AT2 cells were fixed with 4% paraformaldehyde and then incubated with an anti-TREK-1 primary 
antibody (Alomone, 1:200) at 4 °C overnight, followed by probing with a species-specific secondary antibody 
(1:1000; Abcam) for one hour at room temperature. Nuclei were counterstained with Fluoro Gel II mounting 
medium containing DAPI (EMS). All images were recorded using Zen 2009 Light Edition software version 5.5 
(Zeiss; https ://www.zeiss .com/micro scopy /us/produ cts/micro scope -softw are/zen-lite.html).
Cytokine measurements by ELISA. Cytokine concentrations were quantified in BAL fluid and cell cul-
ture supernatants after centrifugation at 8000 rpm for 5 min. Briefly, 100 μL of sample was loaded into 96-well 
ELISA plate, and analyzed following the manufacturer’s instructions. All samples were run in triplicates and 
values are displayed in pg/mL. Species-specific ELISA kits were purchased from the following vendors: IL-6 
(BD Biosciences), IP-10 (mouse: R&D Systems; human: BD Biosciences), CCL-2 (BD Biosciences), TNF-α (BD 
Biosciences), MIP-1α (R&D Systems), IL-10 (R&D Systems).
FLIPR and Fluo‑4 assays for  K+ flux, plasma membrane potential (Em), and intracellular  Ca2+ 
(iCa) measurements. K+ channel activity and Em measurements were performed using commercially 
available FLIPR assays (Molecular Devices, #R8222 and #R8126, respectively), and Fluo-4 assays (Invitrogen, 
#F36206) for iCa measurements. All three assays were performed following the manufacturer’s instructions. 
Briefly, for all assays 30,000 cells/well were seeded into dark-walled, clear-bottom 96-well plates (Grenier Bio-
One, #655090), and cultured in growth medium overnight. The next day, cells were washed once and incubated 
at 37 °C with the respective loading dye for 60 min for  K+ channel activity assays, and 30 min for Em and Fluo-4 
assays. In all assays, fluorescence traces were recorded for 1 min to reach a stable baseline before the addition 
of any drugs. All plates were analyzed using a BioTek Synergy-2 fluorescence plate reader. Data points were col-
lected and integrated every 7 s. To determine whether an increase in iCa concentrations was due to  Ca2+ influx 
via voltage-gated  Ca2+  (CaV) channels, we blocked N- and P/Q-type  CaV channels with ω-conotoxin MVIIC 
(1 μM), and L-type  CaV channels with nifedipine (10 μM).
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Statistical analysis. Quasi-static lung compliance, BAL protein and cell counts, LIS values, cytokine con-
centrations, and FLIPR and Fluo-4 data are represented as Box-Whisker plots with median values, 1st and 3rd 
quartiles, and maximum and minimum values. FLIPR curves in Figs. 5A,B, 6A,B, and 7A,B show mean + SEM 
values. Data were analyzed using the unpaired student t-test, multivariate analysis of variance (ANOVA), and 
pairwise comparison of means using the Tukey–Kramer method to adjust for multiple comparisons. All statisti-
cal analyses were performed using GraphPad Prism 7 software (version 6.04, La Jolla, CA; https ://www.graph 
pad.com/), and p values p ≤ 0.05 were considered significant.
Study approval. Approval for all experiments was obtained from the “University of California Los Angeles 
Animal Research Committee (ARC). All experiments were performed in accordance with our institutional pro-
tocols, guidelines and recommendations.
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